SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration.

Pr Corinne Dot[1] on behalf of the investigators of the SPECTRUM study.
1*Hospices Civils de Lyon – Hopital Edouart Herriot, Lyon*

Presented at the congress of EURETINA 2026 – Free paper session

Disclosures

- Alcon
- Abbvie
- Bayer
- Horus Pharma
- Novartis
- Théa
- Zeiss

SPECTRUM: Global Real-world Study of Aflibercept 8 mg[1,2]

Focus France

24-month non-interventional cohort study, ongoing in 18 countries

2 indications, 4 patient cohorts

treatment-naïve & previously treated **nAMD patients**
treatment-naïve patients & previously treated **DME patients**

Primary endpoint: change in **VA** from **BL to Month 12**

Secondary endpoints include :

Change in VA and **CRT** from BL Month 3 and Month 6

Number of **injections** and **visits**, and **safety profile** through Month 3 and Month 6

Patients included (completed in September 2025[3]):
3733 all cohorts[1,2]

1169	1125	723	716
TN nAMD	PT nAMD	TN DME	PT DME

SPECTRUM in France - nAMD and DME



Patients included (as of September 2025[3]):
295 all cohorts – **29 centers involved**


100	102	93
TN nAMD	PT nAMD	TN DME

TN: treatment-naïve; PT: previously treated; DME: diabetic macular edema; nAMD: neovascular age-related macular degeneration; BL: baseline; VA: visual acuity; CRT: central retinal thickness. 1. Munk MR, et al. FLORetina 2025, 4–7 December 2025, Florence, Italy. 2. Lanzetta P, et al. FLORetina 2025, 4–7 December 2025, Florence, Italy. 3. Bayer. Data on file, November 2025.


Baseline characteristics and 12-month outcomes of previously treated and treatment-naïve patients with neovascular AMD in the French SPECTRUM cohort

Baseline characteristics	Naïve patients[a]	Previously treated[b]
Patients in full analysis set, n	97	99
Mean (SD) age, years	80.6 (6.9)	78.6 (7.9)
Sex, n (%) Female / Male	60 (61.86) 37 (38.14)	62 (62.63) 37 (37.37)
Median (min, max) time from nAMD diagnosis, months	0.1 (0.03; 0.20)	24.3 (1.09; 145.4)
Median last completed treatment interval, weeks	–	6
Mean (SD) VA, ETDRS letters	62.7 (19.46)	70.58 (14.17)
Mean (SD) CRT, µm	363 (143)	278 (107)
MNV type (%) *Type 1 · Type 2 · Mixed* *Type 3 · Missing / Unidentified*	54.64 - 12.4 - 7.2 14.43 - 11.34	68.69 - 10.10 - 4.04 4.04 - 13.13

Previous nAMD treatments (PT, n = 99)



Reason for switching to aflibercept 8 mg[c]




FAS, LOCF (TN: n = 97; PT: n = 99). Percentages may not add up to 100% due to rounding. [a] FAS; Week 24 = visits closest to 180 (150–210) days post-BL. [b] FAS. [c] Reasons for switching: multiple reasons could be selected per patient and are reflective of treatment aims. MNV: macular neovascularization; VA: visual acuity; CRT: central retinal thickness; SRF/IRF: sub-/intraretinal fluid; PED: pigment epithelial detachment; TN: treatment-naïve; PT: previously treated.Corinne Dot, "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration", EURETINA 2026.

Visual acuity outcomes in treatment-naïve and previously treated patients with nAMD

nAMD

Mean VA (treatment-naïve cohort) [a,b]


Mean VA change from baseline (95% CI):	+2.9 letters (0.5; 5.3)	+1.9 letters (-0.9; 4.8)	+3.7 letters (1.4; 6.0)	+3.2 letters (0.1; 6.3)



Mean number of injections: 7.11 up to 12 months

Mean VA (previously treated cohort) [a,b]

Mean VA change from baseline (95% CI):	+0.79 letters (-1.5; 3.1)	+1.6 letters (-0.5; 3.7)	+0.31 letters (-1.1; 1.7)	-0.65 letters (-2.4; 1.0)



Mean number of injections: 6.7 up to 12 months

FAS, LOCF (TN: n=97; PT: n=99). Week 4 = visits closest to 28 (14–42) days post-BL, Week 8 = visits closest to 56 (43–70) days post-BL, Week 24 = visits closest to 180 (150–210) days post-BL. aMissing values were imputed using the LOCF method. [b]Error bars represent the 95% CI.


Corinne Dot "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration" EURETINA 2026

CRT outcomes in treatment-naïve patients and previously treated patients

nAMD


Mean CRT (treatment-naïve cohort)[a,b]

Mean change in CRT from baseline (95% CI):	Baseline	Week 4	Week 8	Week 24	Week 48
	363	-110 µm (−152,7 −68)	-119 µm (−153, −84)	-112 µm (−143, −81)	-10 5µm (−134,6 −76)



Mean CRT (previously treated cohort)[a,b]

Mean change in CRT from baseline (95% CI):	Baseline	Week 4	Week 8	Week 24	Week 48
	279	-23µm (−49.08; 3.38)	-26µm (−48.3; −4.5)	-17 µm (−32.3; -1.08)	-19 µm (−34.8; 2.9)




FAS, LOCF (TN: n=97; PT: n=99). [a]Missing values were imputed using the LOCF method. [b]Error bars represent the 95% CI.

Corinne Dot "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration" EURETINA 2026


Fluid resolution and proportion of patients with retinal fluid through Month 12

nAMD

Proportion of patients with SRF and IRF fluid through 12 months (naïve cohort)[a,b]



Proportion of patients with fluid SRF and IRF through 12 months (previously treated cohort)[a,b]



FAS, LOCF. Values have been rounded to the nearest decimal place. As per the instructions in the case report form, fluid data were collected on OCT during macular evaluation (6 mm) at the discretion of the investigator. [a]Missing values were imputed using the LOCF method. [b]Calculated based on the number of patients assessed at each time point.


Munk MR, et al. FLORetina 2025. December 4–7, 2025. Florence, Italy.

Corinne Dot "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration" EURETINA 2026

Last completed treatment intervals through Week 48

Treatment-naïve patients


Last completed interval at Week 48



Mean treatment interval up to 12 months = 10,37 weeks

Previously treated patients[1]


Last completed interval: pre switch vs. 12 months



Mean treatment interval up to 12 months = 10,37 weeks

Previously treated patients

Proportion of patients with a decreased, maintained or increased last completed treatment interval at Week 48 vs. BL



By Week 48, 70% of patients on an 8-12-week interval at baseline and 50% of patients on any treatment interval at baseline had been extended.

[1] Pre-treated patients: 58.6% switched from aflibercept 2 mg and 28.3% from faricimab 6 mg. Pre switch: q12–15 = 4.2%. Patients with a dosing interval at BL and Week 48 were included. BL: baseline; qX: one injection every X weeks.

Corinne Dot, "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration", EURETINA 2026.

Treatment-emergent adverse events through 12 months in the French cohorts

nAMD

Treatment-naïve cohort

Ocular TEAEs	Total (N=99)
Ocular TEAEs in the study eye, n (%)[a]	7 (7.1)
Serious ocular TEAEs, n (%)	1 (1.0)

Non-ocular TEAEs	Total (N=99)
Non-ocular TEAEs, n (%)	6 (6.1)
Serious non-ocular TEAEs, n (%)	2 (2.0)

Previously treated cohort

Ocular TEAEs	Total (N=102)
Ocular TEAEs in the study eye, n (%)[a]	19 (18.6)
Serious ocular TEAEs, n (%)	2 (2.0)

Non-ocular TEAEs	Total (N=102)
Non-ocular TEAEs, n (%)	7 (6.9)
Serious non-ocular TEAEs, n (%)	3 (2.9)

No cases of retinal vasculitis were reported. No new safety signals.

SAF. [a]The eye treated with aflibercept 8 mg was considered the study eye; if treatment with aflibercept 8 mg was decided simultaneously for both eyes, the study eye was considered to be the most affected eye, at the discretion of the treating physician.

Corinne Dot "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration" EURETINA 2026

12-month analysis of the French SPECTRUM nAMD cohort: Drying, durability and safety shown in the real-world

- **Sustained drying observed in both populations** : −112 µm CRT at Month 12 in treatment-naïve patients, and further drying in previously treated patients

- **Extended intervals with fewer injections were observed**. In naïve patients, 42% reached ≥q12 at Week 48, with only 6.7 injections. In previously treated patients, 70% of those on 8–12-week intervals were extended.

- **Safety :** no cases of IOI or retinal vasculitis with aflibercept 8 mg; **no new safety signals were identified.**

CRT, central retinal thickness; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; q8, every 8 weeks; SmPC, Summary of Product Characteristics; SRF, subretinal fluid.
Corinne Dot "SPECTRUM French cohort analysis: 12-month real-world effectiveness and safety of aflibercept 8 mg in treatment-naïve and previously treated patients with neovascular age-related macular degeneration" EURETINA 2026